LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.82 2.41

Buy Sell

Overview

Share price change

24h

Current

Min

3.74

Max

3.82

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+282.03% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	29M 257M
Previous open	1.41
Previous close	3.82

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 mar 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mar 2026, 23:50 UTC

Market Talk

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

22 mar 2026, 23:49 UTC

Market Talk

Major News Events

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

22 mar 2026, 23:49 UTC

Market Talk

Major News Events

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

22 mar 2026, 23:49 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

22 mar 2026, 23:41 UTC

Market Talk

Major News Events

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

22 mar 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

22 mar 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

22 mar 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

22 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Participated in Aurum Resources Equity Raising

22 mar 2026, 22:54 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

22 mar 2026, 22:22 UTC

Market Talk

Major News Events

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

22 mar 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

22 mar 2026, 21:53 UTC

Earnings

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

22 mar 2026, 21:31 UTC

Earnings

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

22 mar 2026, 21:25 UTC

Market Talk

Major News Events

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

22 mar 2026, 21:22 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

22 mar 2026, 21:21 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

22 mar 2026, 21:21 UTC

Market Talk

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

22 mar 2026, 21:21 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

282.03% upside

12 Months Forecast

Average 14.67 USD 282.03%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.